Clinical Trials Logo

Lung Disease clinical trials

View clinical trials related to Lung Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03085069 Active, not recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Start date: May 3, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, multi-center, phase 2 Study to evaluate SHR-1210(anti-PD-1 antibody) in in adult Chinese patients with advanced or metastatic non-small cell lung cancer who failed or progressed to prior first-line systemic treatment. Enrolled subjects will be assigned to 4 cohorts on the basis of PD-L1 expression in tumor cells(<1%, ≥1%-25%, ≥25%-50%, ≥50%) all will be treated with the standard SHR-1210 dose (200mg) , Q2W, until documented progressive disease (PD) occurs. Subjects will return to the clinic once every two weeks. Radiographic disease assessments will be performed every 6 weeks. The primary study hypothesis is that treatment with SHR-1210 improves Objective Response Rate when compare with standard second-line therapy, no matter how much PD-L1 expression in tumor.